eldecalcitol

Eldecalcitol is a synthetic analog of active vitamin D3 (calcitriol), developed for the treatment of osteoporosis. It acts primarily by inhibiting osteoclast formation, thereby reducing bone resorption, and by promoting calcium absorption in the small intestine. These dual actions improve bone mineral density and strength, leading to a reduced risk of osteoporotic fractures. Eldecalcitol has demonstrated superior efficacy compared to alfacalcidol in increasing lumbar spine bone mineral density and reducing vertebral fracture incidence in postmenopausal women with osteoporosis. The drug was first approved in Japan in 2011 and later approved in China for the treatment of postmenopausal osteoporosis[1][2][5][6].

Brand names

Edirol艾地罗

Other names

艾地骨化醇Eldecalcitol Soft Capsules